Adalimumab for the treatment of uveitis
Adalimumab for the treatment of uveitis
复制标题
DOI：
10.1080/1744666x.2017.1288097
复制
发表时间：
2017-03-01
影响因子：
4.4
通讯作者：
Goldstein, Debra A.
中科院分区：
文献类型：
--
作者：
LaMattina, Kara C.;Goldstein, Debra A.
阿达木单抗是一种肿瘤坏死因子- α (TNF)抑制剂，是唯一被美国食品和药物管理局（FDA）批准用于治疗非感染性葡萄膜炎的全身非皮质类固醇药物。涵盖领域：本综述的目的是总结证明阿达木单抗治疗眼内炎症有效性的研究，并帮助建立其副作用概况，最终导致其获得FDA批准。专家评论：阿达木单抗是治疗非感染性葡萄膜炎的有效二线药物。虽然它只在美国被批准用于成人的中度、后部和全葡萄膜炎，但我发现它对儿童葡萄膜炎和巩膜炎的治疗也很有效。
Introduction: Adalimumab, an inhibitor of tumor necrosis factor-alpha (TNF), is the only systemic non-corticosteroid agent which has been approved by the US Food and Drug Administration (FDA) for the treatment of non-infectious uveitis.Areas covered: The aim of this review is to summarize the research which demonstrated the effectiveness of adalimumab in the treatment of intraocular inflammation and helped to establish its side effect profile, ultimately leading to its FDA approval.Expert commentary: Adalimumab is a useful second-line agent in the treatment of non-infectious uveitis. While it is only approved in the United States for use in intermediate, posterior, and panuveitis in adults, I find it to be effective in off-label treatment of pediatric uveitis and scleritis as well.